

**Clinical trial results:****A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non- Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment**

**Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.nov> for complete trial results.**

**Summary**

EudraCT number	2008-004177-17
Trial protocol	BE FR DE PL IT GR GB AT SK
Global end of trial date	26 December 2018

**Results information**

Result version number	v1 (current)
This version publication date	12 January 2020
First version publication date	12 January 2020

**Trial information****Trial identification**

Sponsor protocol code	COMB157E2301/OMB110918
-----------------------	------------------------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01077518
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Novartis Pharma, AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma, AG, +41 613241111, <a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>
Scientific contact	Clinical Disclosure Office, Novartis Pharma, AG, +41 613241111, <a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
--	----

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 December 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 December 2018
Was the trial ended prematurely?	Yes

Notes:

### General information about the trial

Main objective of the trial:

To establish the effectiveness of ofatumumab in combination with bendamustine (Ofa+Benda) in subjects with indolent B-cell Non-Hodgkin's Lymphoma disease refractory to rituximab-containing therapy

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 August 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 5
Country: Number of subjects enrolled	Austria: 9
Country: Number of subjects enrolled	Belgium: 39
Country: Number of subjects enrolled	Canada: 54
Country: Number of subjects enrolled	France: 26
Country: Number of subjects enrolled	Germany: 15
Country: Number of subjects enrolled	United Kingdom: 7
Country: Number of subjects enrolled	Greece: 23
Country: Number of subjects enrolled	Italy: 31
Country: Number of subjects enrolled	Japan: 26
Country: Number of subjects enrolled	Poland: 29
Country: Number of subjects enrolled	Russian Federation: 54
Country: Number of subjects enrolled	Slovakia: 3

Country: Number of subjects enrolled	Ukraine: 9
Country: Number of subjects enrolled	United States: 16
Worldwide total number of subjects	346
EEA total number of subjects	182

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	195
From 65 to 84 years	149
85 years and over	2

## Subject disposition

### Recruitment

Recruitment details:

346 (173 randomized to Ofa+benda arm and 173 randomized to benda arm)

### Pre-assignment

Screening details:

346 (173 randomized to Ofa+benda arm and 173 randomized to benda arm)

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ofa + benda (Arm A)

Arm description:

ofatumumab and bendamustine arm. Participants received up to 8 cycles of bendamustine (90 mg/m<sup>2</sup>) on Days 1,2 every 21 days with 12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and every 28 days

Arm type	Experimental
Investigational medicinal product name	Ofatumumab
Investigational medicinal product code	OMB157
Other name	Ofa
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.

Investigational medicinal product name	bendamustine
Investigational medicinal product code	
Other name	benda
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intracavernous use

Dosage and administration details:

Bendamustine 100 mg/vial, injection 120 mg/m<sup>2</sup> Days 1 and 2, every 21 days

<b>Arm title</b>	Benda (Arm B)
------------------	---------------

Arm description:

Bendamustine monotherapy. Participants received up to 8 cycles of bendamustine (120 mg/m<sup>2</sup> on Days 1, 2 every 21 days

Arm type	Active comparator
Investigational medicinal product name	bendamustine
Investigational medicinal product code	
Other name	benda
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intracavernous use

Dosage and administration details:

Bendamustine 100 mg/vial, injection 120 mg/m<sup>2</sup> Days 1 and 2, every 21 days

<b>Number of subjects in period 1</b>	Ofa + benda (Arm A)	Benda (Arm B)
Started	173	173
Completed 5-year follow-up	64 <sup>[1]</sup>	64 <sup>[2]</sup>
Completed	95	108
Not completed	78	65
Consent withdrawn by subject	32	28
Physician decision	10	11
Study Terminated by Sponsor	28	22
Lost to follow-up	8	4

---

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This is correct as these subjects completed the study.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This is correct as these subjects completed the study.

## Baseline characteristics

### Reporting groups

Reporting group title	Ofa + benda (Arm A)
-----------------------	---------------------

Reporting group description:

ofatumumab and bendamustine arm. Participants received up to 8 cycles of bendamustine (90 mg/m<sup>2</sup>) on Days 1,2 every 21 days with 12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and every 28 days

Reporting group title	Benda (Arm B)
-----------------------	---------------

Reporting group description:

Bendamustine monotherapy. Participants received up to 8 cycles of bendamustine (120 mg/m<sup>2</sup> on Days 1, 2 every 21 days

Reporting group values	Ofa + benda (Arm A)	Benda (Arm B)	Total
Number of subjects	173	173	346
Age categorical			
Units: Subjects			
Adults (18-64 years)	100	95	195
From 65-84 years	72	77	149
85 years and over	1	1	2
Age Continuous			
Units: years			
arithmetic mean	61.8	62.6	-
standard deviation	± 61.0	± 63.0	-
Sex: Female, Male			
Units: participants			
Female	72	71	143
Male	101	102	203
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	10	6	16
Not Hispanic or Latino	163	167	330
Unknown or Not Reported	0	0	0
FLIPI-1 Score at Screening			
Units: Subjects			
0 - 2	100	93	193
3 - 5	66	75	141
Missing	7	5	12
Baseline Absolute Lymphocyte Count			
Units: Subjects			
< LLN	41	41	82
>= LLN	131	131	262
Missing	1	1	2
FcR Gamma 3A Variation			
Units: Subjects			
The GG	21	18	39
The TG	77	59	136
The TT	61	62	123
Missing	14	34	48

Human Anti-Chimeric Antibodies (HACA) Units: Subjects			
Negative	141	116	257
Positive	21	23	44
Missing	11	34	45

### Subject analysis sets

Subject analysis set title	Optional Ofa
Subject analysis set type	Intention-to-treat
Subject analysis set description: Eligible bende arm participants who were offered optional ofatumumab following disease progression	

Reporting group values	Optional Ofa		
Number of subjects	30		
Age categorical Units: Subjects			
Adults (18-64 years)	21		
From 65-84 years	11		
85 years and over	0		
Age Continuous Units: years			
arithmetic mean	17		
standard deviation	±		
Sex: Female, Male Units: participants			
Female			
Male			
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino			
Not Hispanic or Latino			
Unknown or Not Reported			
FLIPI-1 Score at Screening Units: Subjects			
0 - 2			
3 - 5			
Missing			
Baseline Absolute Lymphocyte Count Units: Subjects			
< LLN			
>= LLN			
Missing			
FcR Gamma 3A Variation Units: Subjects			
The GG			
The TG			
The TT			
Missing			
Human Anti-Chimeric Antibodies (HACA) Units: Subjects			

Negative			
Positive			
Missing			

---

## End points

### End points reporting groups

Reporting group title	Ofa + benda (Arm A)
Reporting group description:	ofatumumab and bendamustine arm. Participants received up to 8 cycles of bendamustine (90 mg/m <sup>2</sup> ) on Days 1,2 every 21 days with 12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and every 28 days
Reporting group title	Benda (Arm B)
Reporting group description:	Bendamustine monotherapy. Participants received up to 8 cycles of bendamustine (120 mg/m <sup>2</sup> on Days 1, 2 every 21 days
Subject analysis set title	Optional Ofa
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Eligible benda arm participants who were offered optional ofatumumab following disease progression

### Primary: Progression-free survival (PFS) as assessed by the Independent Review Committee (IRC)

End point title	Progression-free survival (PFS) as assessed by the Independent Review Committee (IRC)
End point description:	PFS is defined as the time interval between randomization until disease progression or death (due to any cause).
End point type	Primary
End point timeframe:	From randomization to the date of first documented disease progression or death due to any cause (67.5 months)

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: months				
median (confidence interval 95%)	16.66 (12.81 to 19.68)	13.83 (11.30 to 16.89)		

### Statistical analyses

Statistical analysis title	PFS per IRC
Comparison groups	Ofa + benda (Arm A) v Benda (Arm B)
Number of subjects included in analysis	346
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.139
Method	Stratified Log-Rank
Parameter estimate	Stratified Cox propor.hazards regression
Point estimate	0.82

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	1.07

### Secondary: Progression-free survival (PFS) in participants with Follicular Lymphoma (FL) per IRC

End point title	Progression-free survival (PFS) in participants with Follicular Lymphoma (FL) per IRC
-----------------	---

End point description:

PFS is defined as the time interval between randomization until disease progression or death (due to any cause).

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization to the date of first documented disease progression or death due to any cause (67.5 months)

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: months				
median (confidence interval 95%)	16.62 (11.17 to 20.47)	12.12 (10.94 to 16.62)		

### Statistical analyses

<b>Statistical analysis title</b>	PFS for FL per IRC
Comparison groups	Ofa + benda (Arm A) v Benda (Arm B)
Number of subjects included in analysis	346
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1076
Method	Stratified Log-Rank
Parameter estimate	Stratified Cox propor.hazards regression
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.06

**Secondary: Overall response rate (ORR) in All participants per IRC**

End point title	Overall response rate (ORR) in All participants per IRC
-----------------	---

End point description:

ORR: Percentage of subjects achieving a complete response (CR) or partial response (PR) from the start of randomization until disease progression or the start of new anti-cancer therapy, including the optional ofatumumab for subjects in Arm B. based on responses from the IRC assessment of best overall response using the Revised Response Criteria for Malignant Lymphoma (RRCML) with response criteria defined as CR, PR, standard disease (SD), progressive disease (PD) or NE

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until the 217th PFS event occurred, up to about 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Percentage of participants				
number (confidence interval 95%)	73 (66 to 80)	75 (67 to 81)		

**Statistical analyses**

<b>Statistical analysis title</b>	for All participants
Comparison groups	Ofa + benda (Arm A) v Benda (Arm B)
Number of subjects included in analysis	346
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.8003
Method	Cochran-Mantel-Haenszel

**Secondary: Overall response rate (ORR) in participants with FL per IRC**

End point title	Overall response rate (ORR) in participants with FL per IRC
-----------------	---

End point description:

ORR: Percentage of subjects achieving a complete response (CR) or partial response (PR) from the start of randomization until disease progression or the start of new anti-cancer therapy, including the optional ofatumumab for subjects in Arm B. based on responses from the IRC assessment of best overall response using the Revised Response Criteria for Malignant Lymphoma (RRCML) with response criteria defined as CR, PR, standard disease (SD), progressive disease (PD) or NE

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until the 217th PFS event occurred, up to about 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Percentage of participants				
number (confidence interval 95%)	77 (68 to 84)	76 (67 to 83)		

### Statistical analyses

<b>Statistical analysis title</b>	ORR with FL
Statistical analysis description: for Follicular Lymphoma (FL) participants	
Comparison groups	Ofa + benda (Arm A) v Benda (Arm B)
Number of subjects included in analysis	346
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.613
Method	Cochran-Mantel-Haenszel

### Secondary: Overall Survival (OS) in All participants

<b>End point title</b>	Overall Survival (OS) in All participants
End point description: The interval of time between the date of randomization and the date of death due to any cause. For subjects who are alive, time of death will be censored at the date of last contact.	
End point type	Secondary
End point timeframe: From randomization up to about 89 months	

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: months				
median (confidence interval 95%)	59.76 (46.63 to 999)	58.22 (36.44 to 999)		

### Statistical analyses

<b>Statistical analysis title</b>	OS for all patients
Statistical analysis description: for All patients	
Comparison groups	Ofa + benda (Arm A) v Benda (Arm B)

Number of subjects included in analysis	346
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.4046
Method	Stratified Log Rank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	1.21

### Secondary: Overall Survival (OS) in participants with FL

End point title	Overall Survival (OS) in participants with FL
End point description:	The interval of time between the date of randomization and the date of death due to any cause. For subjects who are alive, time of death will be censored at the date of last contact.
End point type	Secondary
End point timeframe:	From randomization up to about 89 months

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: months				
median (confidence interval 95%)	99 (45.60 to 999)	53.59 (36.44 to 999)		

### Statistical analyses

Statistical analysis title	OS for FL patients
Statistical analysis description:	for FL participants
Comparison groups	Ofa + benda (Arm A) v Benda (Arm B)
Number of subjects included in analysis	346
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3768
Method	Stratified Log Rank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.83

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.25

---

### Secondary: Time to response in All participants per IRC

End point title	Time to response in All participants per IRC
End point description: Time to response = time from randomization to the first response (CR/ PR). If no CR/PR value was present data was to be censored at last adequate assessment.	
End point type	Secondary
End point timeframe: From randomization to up to 67.5 months	

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Months				
median (confidence interval 95%)	2.86 (2.83 to 2.92)	2.89 (2.83 to 2.92)		

### Statistical analyses

No statistical analyses for this end point

---

### Secondary: Time to response in participants with FL per IRC

End point title	Time to response in participants with FL per IRC
End point description: Time to response = time from randomization to the first response (CR/ PR). If no CR/PR value was present data was to be censored at last adequate assessment.	
End point type	Secondary
End point timeframe: From randomization to up to 67.5 months	

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Months				
median (confidence interval 95%)	2.86 (2.83 to 2.92)	2.86 (2.83 to 2.89)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of response in All participants per IRC

End point title	Duration of response in All participants per IRC
End point description:	Time (in months) from the initial response (CR/PR) to first documented sign of disease progression or death due to any cause.
End point type	Secondary
End point timeframe:	time from the initial response (CR/PR) (Day 84) to first documented sign of disease progression or death due to any cause up to 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: months				
median (confidence interval 95%)	17.71 (13.04 to 22.57)	14.49 (10.84 to 16.76)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of response in participants with FL per IRC

End point title	Duration of response in participants with FL per IRC
End point description:	Time (in months) from the initial response (CR/PR) to first documented sign of disease progression or death due to any cause.
End point type	Secondary
End point timeframe:	time from the initial response (CR/PR) (Day 84) to first documented sign of disease progression or death due to any cause up to 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: months				
median (confidence interval 95%)	16.39 (11.53 to 20.53)	11.20 (8.61 to 16.43)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to progression in All participants per IRC

End point title	Time to progression in All participants per IRC
End point description:	Time from randomization until disease progression
End point type	Secondary
End point timeframe:	From randomization to the date of first documented disease progression, whichever occurred first, reported between day of first participant randomized up to about 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Months				
median (confidence interval 95%)	19.35 (14.32 to 23.10)	16.56 (13.63 to 19.75)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to progression in participants with FL per IRC

End point title	Time to progression in participants with FL per IRC
End point description:	Time from randomization until disease progression
End point type	Secondary
End point timeframe:	From randomization to the date of first documented disease progression, whichever occurred first, reported between day of first participant randomized up to about 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Months				
median (confidence interval 95%)	19.35 (14.16 to 24.87)	13.80 (11.14 to 16.85)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to next therapy in All participants per IRC

End point title	Time to next therapy in All participants per IRC
End point description:	Time to next therapy was defined as the time (in months) from randomization date to the date of receiving the next line treatment, including all therapy types.
End point type	Secondary
End point timeframe:	from randomization date to the date of receiving the next line treatment or death, up to 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Months				
median (confidence interval 95%)	39.82 (28.81 to 999)	26.94 (21.72 to 39.75)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to next therapy in participants with FL per IRC

End point title	Time to next therapy in participants with FL per IRC
End point description:	Time to next therapy was defined as the time (in months) from randomization date to the date of receiving the next line treatment, including all therapy types
End point type	Secondary
End point timeframe:	from randomization date to the date of receiving the next line treatment or death, up to 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: Months				
median (confidence interval 95%)	36.96 (23.79 to 999)	25.43 (18.37 to 47.70)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PRO - Change from baseline in Health Related Quality of Life (HRQL) measures in All participants: The FACT-Lym

End point title	PRO - Change from baseline in Health Related Quality of Life (HRQL) measures in All participants: The FACT-Lym
-----------------	--

End point description:

The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) is intended as a lymphoma specific additional concerns subscale that is designed to supplement the FACT-G. The subscale consists of 15 items. Subjects respond to the items on a five point Likert scale ranging from 0 'Not at all' to 4 'Very much' and are asked to think back over the past 7 days when responding to each of the items.

C =cycle; D = day

End point type	Secondary
----------------	-----------

End point timeframe:

administered at the Screening visit and at all post-baseline, up to 67.5 months (presented at particular clinically relevant time points)

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: scores on a scale				
arithmetic mean (standard deviation)				
Physical well-being score: C5D1(n=126,118)	0.2 (± 4.36)	-2.8 (± 5.54)		
Physical well-being score C11D1(n=104,78)	1.1 (± 4.58)	1.0 (± 4.25)		
Physical well-being score D252 (n=3, 6)	-5.0 (± 9.64)	1.7 (± 9.18)		
Physical well-being score 12M post-D252 (n=67,53)	0.9 (± 5.59)	1.3 (± 4.52)		
Physical well-being score Withdrawal(n=12, 15)	-4.1 (± 6.78)	-1.5 (± 6.61)		
Social/Family well-being score C5D1(n=126,118)	0.2 (± 4.94)	-0.5 (± 5.24)		
Social/Family well-being score C11D1(n=104,78)	-1.2 (± 6.09)	-1.1 (± 6.45)		
Social/Family well-being score D252 (n=3,6)	-1.6 (± 3.24)	-5.4 (± 9.08)		
Soc./Fam. well-being score 12M post-D252(n=67,53)	0.3 (± 5.21)	-1.3 (± 4.81)		

Social/Family well-being score Withdrawal(n=12,15)	0.9 (± 7.69)	0.3 (± 3.53)		
Emotional well-being score C5D1(n=126,118)	1.7 (± 3.97)	0.1 (± 4.10)		
Emotional well-being score C11D1(n=103,78)	1.4 (± 4.12)	0.7 (± 3.90)		
Emotional well-being score D252(n=3,6)	-5.3 (± 2.08)	-2.5 (± 5.89)		
Emotional well-being score 12M post- D252(n=67,53)	1.5 (± 4.45)	0.7 (± 4.15)		
Emotional well-being score Withdrawal(n=12,15)	-2.2 (± 4.80)	-2.3 (± 4.12)		
Functional well-being score C5D1(n=126,118)	0.7 (± 5.08)	-1.5 (± 5.79)		
Functional well-being score C11D1(n=103,78)	1.1 (± 5.62)	-0.6 (± 5.52)		
Functional well-being score D252(n=3, 6)	-4.3 (± 5.69)	-2.2 (± 13.76)		
Functional well-being score 12M post- D252(n=67,53)	1.1 (± 4.82)	0.8 (± 5.55)		
Functional well-being score Withdrawal(n=12,15)	-2.3 (± 4.27)	-1.6 (± 6.47)		
Lymphoma subscale score C5D1(n=126,118)	3.6 (± 7.88)	-1.0 (± 9.65)		
Lymphoma subscale score C11D1(n=104,78)	4.4 (± 8.88)	2.3 (± 6.53)		
Lymphoma subscale score D252(n=3, 6)	-2.3 (± 14.98)	0.7 (± 18.22)		
Lymphoma subscale score 12M post- D252(n=67,53)	3.2 (± 7.77)	2.0 (± 7.71)		
Lymphoma subscale score Withdrawal(n=12,15)	-1.4 (± 6.16)	-1.6 (± 7.65)		
FACT-Lymphoma TOI C1D1(n=126, 118)	4.5 (± 14.64)	-5.3 (± 18.67)		
FACT-Lymphoma TOI C11D1(n=103,78)	6.7 (± 15.84)	2.7 (± 13.24)		
FACT-Lymphoma TOI D252 (n=3, 6)	-11.7 (± 28.75)	0.2 (± 36.56)		
FACT-Lymphoma TOI 12M post-D252 (n=67,53)	5.1 (± 15.94)	4.1 (± 14.62)		
FACT-Lymphoma TOI Withdrawal(n=12,14)	-7.8 (± 14.55)	-4.3 (± 16.77)		
FACT-G Total Score C5D1 (n=126,118)	2.7 (± 12.82)	-4.7 (± 15.26)		
FACT-G Total Score C11D1 (n=103,78)	2.3 (± 13.00)	0.1 (± 14.11)		
FACT-G Total score D252 (n=3, 6)	-16.2 (± 15.71)	-8.4 (± 31.22)		
FACT-G Total Score 12M post- D252(n=67, 53)	3.7 (± 13.75)	1.5 (± 13.44)		
FACT-G Total Score Withdrawal (n=12, 15)	-7.7 (± 11.91)	-5.3 (± 13.10)		
FACT-Lymph. Tot. score C5D1 (n=126,118)	6.3 (± 18.78)	-5.8 (± 23.05)		
FACT-Lymph. Tot. score C11D1 (n=103,78)	6.7 (± 18.95)	2.4 (± 18.73)		
FACT-Lymph. Tot. score D252(n=3, 6)	-18.6 (± 30.50)	-7.7 (± 44.64)		
FACT-Lymph. Tot. score 12M post-D252 (n=67, 53)	6.9 (± 19.78)	3.5 (± 18.77)		
FACT-Lymph. Tot. score Withdrawal (n=12, 14)	-9.1 (± 15.96)	-6.5 (± 18.53)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PRO - Change from baseline in Health Related Quality of Life (HRQL) measures in participants with FL: The FACT-Lym

End point title	PRO - Change from baseline in Health Related Quality of Life (HRQL) measures in participants with FL: The FACT-Lym
-----------------	--

End point description:

The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) is intended as a lymphoma specific additional concerns subscale that is designed to supplement the FACT-G. The subscale consists of 15 items. Subjects respond to the items on a five point Likert scale ranging from 0 'Not at all' to 4 'Very much' and are asked to think back over the past 7 days when responding to each of the items.

End point type	Secondary
----------------	-----------

End point timeframe:

administered at the Screening visit and at all post-baseline, up to 67.5 months (presented at particular clinically relevant time points)

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: scores on a scale				
arithmetic mean (standard deviation)				
Physical well-being score C5D1(n=87,78)	0.0 (± 4.66)	-3.4 (± 5.87)		
Physical well-being score C11D1(n=72,47)	0.9 (± 4.16)	1.2 (± 4.74)		
Physical well-being score D252 (n=1, 2)	2.0 (± 999)	7.5 (± 17.68)		
Physical well-being score 12M post-D252 (n=48, 30)	0.5 (± 6.15)	1.8 (± 4.37)		
Physical well-being score Withdrawal(n=6,11 )	-5.0 (± 7.64)	-0.6 (± 6.31)		
Social/Family well-being score C5D1(n=87,78)	-0.1 (± 4.38)	-0.7 (± 5.48)		
Social/Family well-being score C11D1(n=72,47)	-1.6 (± 5.38)	-1.4 (± 5.61)		
Social/Family well-being score D252 (n=1, 2)	2.0 (± 999)	2.5 (± 3.54)		
Soc./Fam. well-being score 12M post-D252(n=48,30)	0.3 (± 5.35)	-1.9 (± 5.14)		
Social/Family well-being score Withdrawal(n=6,11)	1.1 (± 5.79)	0.6 (± 2.57)		
Emotional well-being score C5D1(n=87,78)	1.8 (± 3.65)	-0.0 (± 4.41)		
Emotional well-being score C11D1(n=72, 47)	1.2 (± 4.30)	0.5 (± 4.10)		

Emotional well-being score D252(n=1,2)	-6.0 (± 9.99)	-1.0 (± 9.90)		
Emotional well-being score 12M post-D252(n=48,30)	1.5 (± 4.85)	0.6 (± 2.68)		
Emotional well-being score Withdrawal(n=6,11)	-2.3 (± 5.28)	-1.9 (± 4.59)		
Functional well-being score C5D1(n=87,78)	0.1 (± 4.58)	-1.7 (± 5.74)		
Functional well-being score C11D1(n=72,47)	0.5 (± 4.99)	-0.0 (± 4.84)		
Functional well-being score D252(n=1,2)	-6.0 (± 9.99)	7.0 (± 15.56)		
Functional well-being score 12M post-D252(n=48,30)	0.7 (± 4.99)	1.0 (± 5.75)		
Functional well-being score Withdrawal(6,11)	-1.6 (± 4.06)	-1.5 (± 7.15)		
Lymphoma subscale score C5D1(n=87,78)	3.7 (± 7.33)	-2.2 (± 9.71)		
Lymphoma subscale score C11D1(n=72,47)	3.7 (± 8.70)	2.4 (± 6.79)		
Lymphoma subscale score D252(n=1,2)	-18.7 (± 9.99)	7.0 (± 38.18)		
Lymphoma subscale score 12M post-D252(n=48,30)	2.6 (± 8.00)	2.2 (± 6.63)		
Lymphoma subscale score Withdrawal(n=6,11)	-2.5 (± 6.76)	-0.4 (± 7.17)		
FACT-Lymphoma TOI C5D1(n=87,78)	3.7 (± 13.51)	-7.3 (± 18.77)		
FACT-Lymphoma TOI C11D1(n=72,47)	5.0 (± 14.74)	3.6 (± 14.01)		
FACT-Lymphoma TOI D252(n=1,2)	-2.0 (± 9.99)	21.5 (± 71.42)		
FACT-Lymphoma TOI 12M post-D252(n=48,30)	3.7 (± 16.94)	4.9 (± 12.32)		
FACT-Lymphoma TOI Withdrawal(n=6,10)	-9.2 (± 15.40)	-1.7 (± 15.26)		
FACT-G Total score C5D1(n=87,78)	1.7 (± 11.40)	-5.8 (± 16.32)		
FACT-G Total score C11D1(n=72,47)	1.0 (± 12.17)	0.2 (± 13.96)		
FACT-G Total score D252(n=1,2)	-8.0 (± 9.99)	16.0 (± 39.60)		
FACT-G Total score 12M post-D252(n=48,30)	2.9 (± 14.62)	1.4 (± 11.25)		
FACT-Lymphoma Tot. score C5D1(n=87,78)	5.4 (± 16.55)	-8.0 (± 24.11)		
FACT-Lymphoma Tot. score C11D1(n=72,47)	4.7 (± 17.52)	2.7 (± 19.60)		
FACT-Lymphoma Tot. score D252(n=1,2)	-6.0 (± 9.99)	23.0 (± 77.78)		
FACT-Lymphoma Tot. score 12M post-D252(n=48,30)	5.5 (± 20.73)	3.6 (± 14.44)		
FACT-Lymphoma Tot. score Withdrawal(n=6,10)	-10.4 (± 15.02)	-3.1 (± 18.48)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: PRO - Change from baseline in HRQL measures in all participants: The EQ-5D

End point title	PRO - Change from baseline in HRQL measures in all participants: The EQ-5D
-----------------	--

End point description:

The EuroQoL Five-Dimension (EQ-5D) is a self-administered, generic, indirect utility measure used for health economic analysis. It consists of a 0-100 Visual Analogue Scale (VAS) on which subjects are asked to rate their current overall health status & 5 single-item dimensions which ask subjects to rate their health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items can be summed and expressed as a single global index of health-related quality of life. For each of the 5 items subjects must choose between 3 levels of difficulty in accomplishing tasks in that dimension. The VAS is then used in combination with the dimension scores to generate a subject profile. 1 response exists per dimension: Level 1 (no problem) is coded as "1"; Level 2 (some or moderate problems) is coded as "2"; Level 3 (unable, or extreme problems) is coded as "3".

End point type	Secondary
----------------	-----------

End point timeframe:

administered at the Screening visit and at all post-baseline, up to 67.5 months (presented at particular clinically relevant time points)

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: scores on a scale				
arithmetic mean (standard deviation)				
EQ5D01-EQ VAS Score C5D1(n=124,115)	5.8 (± 18.10)	-3.8 (± 19.25)		
EQ5D01-EQ VAS Score C11D1(n=101,78)	12.9 (± 19.38)	2.7 (± 18.96)		
EQ5D01-EQ VAS Score D252 (n=3,6)	-11.7 (± 16.07)	-0.8 (± 19.66)		
EQ5D01-EQ VAS Score 12M post-D252(n=65,52)	14.7 (± 19.71)	7.1 (± 19.14)		
EQ5D01-EQ VAS Score Withdrawal (n=12, 15)	-14.7 (± 17.03)	0.7 (± 34.41)		
EuroQoL Tariffs C5D1(n=122,116)	0.21 (± 0.24)	0.0 (± 0.22)		
EuroQoL Tariffs C11D1(n=102,78)	0.1 (± 0.22)	0.0 (± 0.19)		
EuroQoL Tariffs D252 (n=3, 6)	-0.4 (± 0.79)	0.1 (± 0.36)		
EuroQoL Tariffs 12M post-D252(n=65,51)	0.0 (± 0.22)	0.0 (± 0.20)		
EuroQoL Tariffs Withdrawal (n=12,15)	-0.2 (± 0.22)	0.1 (± 0.32)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: PRO - Change from baseline in HRQL measures in participants with FL: The EQ-5D

End point title	PRO - Change from baseline in HRQL measures in participants with FL: The EQ-5D
-----------------	--

End point description:

The EuroQoL Five-Dimension (EQ-5D) is a self-administered, generic, indirect utility measure used for health economic analysis. It consists of a 0-100 Visual Analogue Scale (VAS) on which subjects are asked to rate their current overall health status & 5 single-item dimensions which ask subjects to rate their health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items can be summed and expressed as a single global index of health-related quality of life. For each of the 5 items subjects must choose between 3 levels of difficulty in accomplishing tasks in that

dimension. The VAS is then used in combination with the dimension scores to generate a subject profile. 1 response exists per dimension: Level 1 (no problem) is coded as "1"; Level 2 (some or moderate problems) is coded as "2"; Level 3 (unable, or extreme problems) is coded as "3".

End point type	Secondary
End point timeframe:	
administered at the Screening visit and at all post-baseline, up to 67.5 months (presented at particular clinically relevant time points)	

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	119		
Units: scores on a scale				
arithmetic mean (standard deviation)				
EQ5D01-EQ VAS Score C5D1(n=85,76)	5.5 (± 19.25)	-6.5 (± 18.83)		
EQ5D01-EQ VAS Score C11D1(n=69,47)	12.9 (± 19.88)	1.1 (± 20.87)		
EQ5D01-EQ VAS Score D252 (n=1,2)	0.00 (± 999)	-7.5 (± 31.82)		
EQ5D01-EQ VAS Score 12M post-D252(n=46,29)	14.2 (± 21.47)	6.7 (± 20.77)		
EQ5D01-EQ VAS Score Withdrawal (n=6,11)	-18.5 (± 13.35)	5.4 (± 37.78)		
EuroQoL Tariffs C5D1(n=84, 76)	0.0 (± 0.24)	0.0 (± 0.23)		
EuroQoL Tariffs C11D1(n=70, 47))	0.1 (± 0.22)	0.0 (± 0.20)		
EuroQoL Tariffs D252 (n=1, 2)	0.0 (± 999)	0.4 (± 0.53)		
EuroQoL Tariffs 12M post-D252(n=46,28)	0.0 (± 0.22)	0.0 (± 0.16)		
EuroQoL Tariffs Withdrawal (n=6,11)	-0.1 (± 0.16)	0.1 (± 0.36)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PRO - Change in health treatment in HRQL measures in all participants: The Health Change Questionnaire (HCQ)

End point title	PRO - Change in health treatment in HRQL measures in all participants: The Health Change Questionnaire (HCQ)
End point description:	
The Health Change Questionnaire, (HCQ) used is a nine item scale that asks the patient to rate change in status since beginning treatment on this study. Subject response provides an ongoing evaluation of perceived progress and satisfaction with treatment services.	
End point type	Secondary
End point timeframe:	
administered at the Screening visit and at all post-baseline, up to 67.5 months (presented at particular clinically relevant time points)	

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: scores on a scale				
arithmetic mean (standard deviation)				
Change in health treatment C5D1(n=124, 118)	2.8 (± 1.81)	3.8 (± 2.29)		
Change in health treatment C11D1(n=105, 77)	2.6 (± 1.73)	2.5 (± 1.74)		
Change in health treatment D252(n=3, 6)	5.3 (± 2.52)	4.8 (± 2.56)		
Change in health treatment 12M post D252(n=66, 50)	2.4 (± 1.95)	2.6 (± 1.99)		
Change in health treatment Withdrawal (n=11, 15)	5.4 (± 3.32)	4.3 (± 2.63)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: PRO - Change in health treatment in HRQL measures in participants with FL: The Health Change Questionnaire (HCQ)

End point title	PRO - Change in health treatment in HRQL measures in participants with FL: The Health Change Questionnaire (HCQ)
-----------------	--

End point description:

The Health Change Questionnaire, (HCQ) used is a nine item scale that asks the patient to rate change in status since beginning treatment on this study. Subject response provides an ongoing evaluation of perceived progress and satisfaction with treatment services.

End point type	Secondary
----------------	-----------

End point timeframe:

administered at the Screening visit and at all post-baseline, up to 67.5 months (presented at particular clinically relevant time points)

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	119		
Units: scores on a scale				
arithmetic mean (standard deviation)				
Change in health treatment C5D1(n=86, 78)	2.9 (± 1.93)	3.9 (± 2.25)		
Change in health treatment C11D1(n=73, 46)	2.7 (± 1.73)	2.4 (± 1.56)		
Change in health treatment D252(n=1, 2)	3.0 (± 999)	4.5 (± 3.54)		
Change in health treatment 12M post D252(n=47,27)	2.7 (± 2.11)	2.1 (± 1.54)		
Change in health treatment Withdrawal (n=5,11)	7.2 (± 1.79)	4.2 (± 2.96)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Reduction in tumor size

End point title | Reduction in tumor size

End point description:

Tumor size was measured by the mean change in the sum of the products of the greatest diameter (SPD) of the largest abnormal nodes from baseline to post-baseline by CT Scan.

End point type | Secondary

End point timeframe:

baseline, post-baseline (up to 55 months)

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: mm <sup>2</sup>				
arithmetic mean (standard deviation)	-33.2 (± 44.08)	-32.8 (± 36.83)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Improvement in Eastern Cooperative Oncology Group (ECOG) Performance status

End point title | Improvement in Eastern Cooperative Oncology Group (ECOG) Performance status

End point description:

Improvement was defined as decrease from baseline by at least one step on the ECOG performance status scale (improvement categorized as yes or no).

End point type | Secondary

End point timeframe:

from baseline to End of study up to 67.5 months

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: participants				
C5D1 (n= 142, 134): Deteriorated	18	24		
C5D1 (n= 142, 134): Improved	30	22		
C5D1 (n= 142, 134): No Change	94	88		
C11D1 (n= 115, 90): Deteriorated	13	9		
C11D1 (n= 115, 90): Improved	27	23		
C11D1 (n= 115, 90): No Change	75	58		
12M post D252 (n= 70, 56): Deteriorated	9	6		
12M post-D252 (n= 70, 56): Improved	17	12		
12M post-D252 (n= 70, 56): No Change	44	38		
Withdrawal (n= 17, 21): Deteriorated	7	8		
Withdrawal (n= 17, 21): Improved	2	2		
Withdrawal (n= 17, 21): No Change	8	11		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Summary of number of participants with Human Anti-Human Antibodies (HAHA)

End point title	Summary of number of participants with Human Anti-Human Antibodies (HAHA) <sup>[1]</sup>
End point description:	A summary by responders and non-responders
End point type	Secondary
End point timeframe:	From randomization up to about 67.5 months

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis was planned for this endpoint.

<b>End point values</b>	Ofa + benda (Arm A)			
Subject group type	Reporting group			
Number of subjects analysed	172			
Units: Participants				
with Post-Ofatumumab HAHA results with at least 1 conf. +ve post-Ofa HAHA result	151			
-ve post-Ofa HAHA results, no Ofa conc. <200 ug/mL	6			
-ve post-Ofa HAHA, at least 1 Ofa conc<200ug/mL	144			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall response rate (ORR) to optional ofatumumab monotherapy in subjects who progressed during or following single-agent bendamustine

End point title	Overall response rate (ORR) to optional ofatumumab monotherapy in subjects who progressed during or following single-agent bendamustine
-----------------	---

End point description:

Percentage of subjects achieving a CR or PR from the start of randomization until disease progression or the start of new anti-cancer therapy, including the optional ofatumumab for subjects in Arm B. Based on responses from the IRC assessment of best overall response using the Revised Response Criteria for Malignant Lymphoma (RRCML) with response criteria defined as CR, PR, SD, PD or NE

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until the 217th PFS event occurred, up to about 67.8 months

End point values	Optional Ofa			
Subject group type	Subject analysis set			
Number of subjects analysed	30			
Units: Percentage of participants	17			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Quantitative assessments of immunoglobulins A, G and M (IgA, IgG, IgM)

End point title	Quantitative assessments of immunoglobulins A, G and M (IgA, IgG, IgM) <sup>[2]</sup>
-----------------	---

End point description:

at scheduled visits for actual values as well as for change from baseline

End point type	Secondary
----------------	-----------

End point timeframe:

prior to receiving ofatumumab, at first monthly dose, and at 1, 3, and 6 months post last infusion of ofatumumab

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis was planned for this endpoint.

<b>End point values</b>	Ofa + benda (Arm A)			
Subject group type	Reporting group			
Number of subjects analysed	173			
Units: g/L				
arithmetic mean (standard deviation)				
IgA @ screening (BL) (n=1)	0.7 (± 999)			
IgG @ screening (n=1)	4.7 (± 999)			
IgM @ screening (n=1)	0.6 (± 999)			
IgA @ C1D1 (n=134)	1.3 (± 0.78)			
IgG @ C1D1 (n=153)	7.7 (± 3.96)			
IgM @ C1D1 (n=120)	1.4 (± 4.15)			
IgA @ 1M post-D252 (n=77)	1.1 (± 0.74)			
IgG @ 1M post-D252 (n=90)	7.1 (± 2.90)			
IgM @ 1M post-D252 (n=50)	0.6 (± 0.68)			
IgA @ 6M post D252 (n=65)	1.1 (± 0.59)			
IgG @ 6M post D252 (n=75)	7.3 (± 2.97)			
IgM @ 6M post D252 (n=41)	0.7 (± 0.97)			
IgA @ 12M post D252 (n=53)	1.1 (± 1.2)			
IgG @12M post D252 (n=63)	7.1 (± 3.31)			
IgM @ 12M post D252 (n=41)	0.7 (± 0.66)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Plasma ofatumumab concentrations

End point title	Plasma ofatumumab concentrations <sup>[3]</sup>
End point description:	Concentrations of ofatumumab in plasma listed by actual relative time and summarized by nominal time.
End point type	Secondary
End point timeframe:	Cycle 1 Day 1 up to 12 months follow up

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistical analysis was planned for this endpoint.

<b>End point values</b>	Ofa + benda (Arm A)			
Subject group type	Reporting group			
Number of subjects analysed	173			
Units: ug/mL				
arithmetic mean (standard deviation)				
C1D1 End of infusion (EOI) (n=64)	262.0 (± 83.97)			
C1D1 1h post-EOI (n=61)	283.2 (± 227.11)			
C7D1 pre-dose (n=128)	153.6 (± 74.45)			

C7D1 EOI (n=42)	402.2 (± 148.78)			
C7D1 1h post-EOI (n=39)	419.1 (± 167.44)			
C12D1 pre-dose (n=101)	143.5 (± 75.58)			
C12D1 EOI (n=27)	392.0 (± 130.64)			
12M post-D252 (n=43)	0.9 (± 2.53)			
Withdrawal (n=13)	29.6 (± 42.58)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Participants with complete B-cell depletion and near-complete B-cell depletion: B-cell monitoring (CD19+, CD20+)

End point title	Participants with complete B-cell depletion and near-complete B-cell depletion: B-cell monitoring (CD19+, CD20+)
-----------------	--

End point description:

The percent change of CD5+CD19+ and CD5-CD19+ from baseline was summarized to assess the treatment effect, to monitor the normal B-cell population, and to follow their recovery.

Complete B-cell depletion is defined as the absolute value of CD5+CD19+ and CD5-CD19+ both equal to zero cells/uL.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to 18 months follow up

End point values	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: percentage change from baseline arithmetic mean (standard deviation)				
C5D1: CD45+CD19+ (n=18, 1)	-94.0 (± 16.6)	-97.0 (± 999)		
1M post-D252: CD45+CD19+ (n=27, 0)	-82.0 (± 77.0)	999 (± 999)		
9M post-D252: CD45+CD19+ (n=15, 0)	1421.0 (± 5721.6)	999 (± 999)		
C1D1: CD45+CD20+ (n=17,1)	-100.0 (± 0.0)	-98.0 (± 999)		
1M post-D252: CD45+CD20+ (n=26, 0)	-100.0 (± 0.0)	999 (± 999)		
9M post-D252: CD45+CD20+ (n=15, 0)	925.0 (± 3803.1)	999 (± 999)		

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Human Anti-chimeric Antibodies (HACA) Over Time**

---

End point title	Human Anti-chimeric Antibodies (HACA) Over Time
-----------------	---

End point description:

The percentage of participants with positive and negative baseline HACA results

End point type	Secondary
----------------	-----------

End point timeframe:

At Baseline and Cycle 1 day 1

---

<b>End point values</b>	Ofa + benda (Arm A)	Benda (Arm B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	173	173		
Units: percentage of participants				
Baseline: Negative (n = 172, 170)	86	70		
Baseline: Positive (n = 172, 170)	13	14		
C1D1: Negative (n=170, 142)	87	84		
C1D1:Positive (n=170, 142)	13	16		

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Total
-----------------------	-------

Reporting group description:

Total

Reporting group title	OFA + BENDA
-----------------------	-------------

Reporting group description:

OFA + BENDA

Reporting group title	BENDA
-----------------------	-------

Reporting group description:

BENDA

Reporting group title	Optional OFA
-----------------------	--------------

Reporting group description:

Optional OFA

<b>Serious adverse events</b>	Total	OFA + BENDA	BENDA
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	160 / 342 (46.78%)	72 / 172 (41.86%)	84 / 170 (49.41%)
number of deaths (all causes)	137	66	71
number of deaths resulting from adverse events	0	0	0
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
Acute myeloid leukaemia			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Adenocarcinoma gastric			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma pancreas			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Basal cell carcinoma</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Benign ovarian tumour</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Brain neoplasm</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Burkitt's lymphoma</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Colon cancer metastatic</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Diffuse large B-cell lymphoma</b>			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Lung adenocarcinoma</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lung neoplasm malignant</b>			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Malignant melanoma</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Myelodysplastic syndrome</b>			
subjects affected / exposed	3 / 342 (0.88%)	2 / 172 (1.16%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 1
<b>Myelofibrosis</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Pancreatic carcinoma</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Transitional cell carcinoma</b>			
subjects affected / exposed	2 / 342 (0.58%)	2 / 172 (1.16%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tumour haemorrhage</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tumour pain</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
Aortic aneurysm			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Aortic aneurysm rupture</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Circulatory collapse</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Embolism</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Hypertension</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Jugular vein thrombosis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lymphoedema</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Subclavian vein thrombosis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			
Asthenia			

subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Death</b>			
subjects affected / exposed	4 / 342 (1.17%)	3 / 172 (1.74%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 4	0 / 3	0 / 1
<b>Disease progression</b>			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
<b>Fatigue</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General physical health deterioration</b>			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
<b>Malaise</b>			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Mucosal inflammation</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Multiple organ dysfunction syndrome</b>			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
<b>Pyrexia</b>			

subjects affected / exposed	16 / 342 (4.68%)	7 / 172 (4.07%)	9 / 170 (5.29%)
occurrences causally related to treatment / all	0 / 0	4 / 8	6 / 10
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Systemic inflammatory response syndrome</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Immune system disorders</b>			
<b>Hypersensitivity</b>			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Type IV hypersensitivity reaction</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Social circumstances</b>			
<b>Loss of personal independence in daily activities</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>Acute pulmonary oedema</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchiectasis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Chronic obstructive pulmonary disease</b>			

subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Dyspnoea</b>			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemoptysis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pleural effusion</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia aspiration</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Pneumonitis</b>			
subjects affected / exposed	5 / 342 (1.46%)	1 / 172 (0.58%)	4 / 170 (2.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Productive cough</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary embolism</b>			
subjects affected / exposed	4 / 342 (1.17%)	3 / 172 (1.74%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary oedema</b>			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pulmonary thrombosis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory distress</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory failure</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Psychiatric disorders</b>			
<b>Abnormal behaviour</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Confusional state</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Depression</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Investigations</b>			
<b>Cytomegalovirus test positive</b>			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutrophil count decreased</b>			

subjects affected / exposed	2 / 342 (0.58%)	2 / 172 (1.16%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw fracture			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Acute coronary syndrome			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Cardiac failure chronic			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Coronary artery disease			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Myocardial infarction</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Sinus tachycardia</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Supraventricular tachycardia</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tachycardia</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ventricular tachycardia</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>Cerebral haemorrhage</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Cerebrovascular accident</b>			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 1
<b>Generalised tonic-clonic seizure</b>			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Lethargy</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Paraparesis</b>			
subjects affected / exposed	2 / 342 (0.58%)	2 / 172 (1.16%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Status epilepticus</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Syncope</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Transient ischaemic attack</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular encephalopathy</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	12 / 342 (3.51%)	2 / 172 (1.16%)	10 / 170 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 2	9 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Aplastic anaemia</b>			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Autoimmune haemolytic anaemia</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile neutropenia</b>			
subjects affected / exposed	15 / 342 (4.39%)	8 / 172 (4.65%)	5 / 170 (2.94%)
occurrences causally related to treatment / all	0 / 0	8 / 9	6 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemolytic anaemia</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Haemorrhagic anaemia</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Leukopenia</b>			
subjects affected / exposed	4 / 342 (1.17%)	1 / 172 (0.58%)	3 / 170 (1.76%)
occurrences causally related to treatment / all	0 / 0	0 / 1	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			
subjects affected / exposed	14 / 342 (4.09%)	6 / 172 (3.49%)	8 / 170 (4.71%)
occurrences causally related to treatment / all	0 / 0	8 / 9	9 / 9
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Pancytopenia</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombocytopenia</b>			

subjects affected / exposed	8 / 342 (2.34%)	2 / 172 (1.16%)	6 / 170 (3.53%)
occurrences causally related to treatment / all	0 / 0	2 / 2	5 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Thrombocytopenic purpura			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic atrophy			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal artery occlusion			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal perforation			

subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Faecalith</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal haemorrhage</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nausea</b>			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Small intestinal obstruction</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Stomatitis</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vomiting</b>			
subjects affected / exposed	3 / 342 (0.88%)	2 / 172 (1.16%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
<b>Drug-induced liver injury</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatorenal syndrome</b>			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Hyperbilirubinaemia</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Portal vein thrombosis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Dermatitis</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Paraneoplastic pemphigus</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Stevens-Johnson syndrome</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Toxic epidermal necrolysis</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Urticaria</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			

Acute kidney injury			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Urinary tract inflammation			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Acinetobacter bacteraemia			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0

Atypical pneumonia			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Candida infection			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus chorioretinitis			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dysentery</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Escherichia urinary tract infection</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile infection</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Herpes ophthalmic</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Herpes zoster</b>			
subjects affected / exposed	5 / 342 (1.46%)	1 / 172 (0.58%)	4 / 170 (2.35%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Herpes zoster disseminated</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infective exacerbation of chronic obstructive airways disease</b>			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Lung infection			
subjects affected / exposed	5 / 342 (1.46%)	3 / 172 (1.74%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	2 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic infection			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pharyngitis			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumocystis jirovecii infection</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumocystis jirovecii pneumonia</b>			
subjects affected / exposed	3 / 342 (0.88%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Pneumonia</b>			
subjects affected / exposed	25 / 342 (7.31%)	10 / 172 (5.81%)	14 / 170 (8.24%)
occurrences causally related to treatment / all	0 / 0	4 / 10	6 / 15
deaths causally related to treatment / all	0 / 8	0 / 2	0 / 6
<b>Pneumonia cytomegaloviral</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Postoperative abscess</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Progressive multifocal leukoencephalopathy</b>			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Pulmonary sepsis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory tract infection</b>			

subjects affected / exposed	3 / 342 (0.88%)	2 / 172 (1.16%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sepsis</b>			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Septic shock</b>			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 2
<b>Sinusitis</b>			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin infection</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Spinal cord infection</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Staphylococcal sepsis</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Staphylococcal skin infection</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Subcutaneous abscess</b>			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tuberculosis</b>			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	2 / 342 (0.58%)	0 / 172 (0.00%)	2 / 170 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Urinary tract infection</b>			
subjects affected / exposed	2 / 342 (0.58%)	2 / 172 (1.16%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Urosepsis</b>			
subjects affected / exposed	2 / 342 (0.58%)	1 / 172 (0.58%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
<b>Varicella</b>			
subjects affected / exposed	1 / 342 (0.29%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>Decreased appetite</b>			
subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dehydration</b>			
subjects affected / exposed	3 / 342 (0.88%)	0 / 172 (0.00%)	3 / 170 (1.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Diabetes mellitus</b>			

subjects affected / exposed	1 / 342 (0.29%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Failure to thrive</b>			
subjects affected / exposed	2 / 342 (0.58%)	2 / 172 (1.16%)	0 / 170 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
<b>Hypokalaemia</b>			
subjects affected / exposed	3 / 342 (0.88%)	0 / 172 (0.00%)	3 / 170 (1.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Optional OFA		
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	8 / 32 (25.00%)		
number of deaths (all causes)	15		
number of deaths resulting from adverse events	0		
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Acute myeloid leukaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Adenocarcinoma gastric</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Adenocarcinoma pancreas</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Basal cell carcinoma</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Benign ovarian tumour				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brain neoplasm				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Burkitt's lymphoma				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colon cancer metastatic				
subjects affected / exposed	1 / 32 (3.13%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diffuse large B-cell lymphoma				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung adenocarcinoma				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung neoplasm malignant				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myelodysplastic syndrome				

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Myelofibrosis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pancreatic carcinoma</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Transitional cell carcinoma</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Tumour haemorrhage</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Tumour pain</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Vascular disorders</b>			
<b>Aortic aneurysm</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Aortic aneurysm rupture</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Circulatory collapse</b>			

subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>Embolism</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hypertension</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Jugular vein thrombosis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Lymphoedema</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Subclavian vein thrombosis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>General disorders and administration site conditions</b>			
<b>Asthenia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Death</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Disease progression</b>			

subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
<b>Fatigue</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>General physical health deterioration</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Malaise</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Mucosal inflammation</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Multiple organ dysfunction syndrome</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pyrexia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Systemic inflammatory response syndrome</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Immune system disorders</b>			
Hypersensitivity			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Type IV hypersensitivity reaction			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Loss of personal independence in daily activities			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiectasis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia aspiration			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Productive cough			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary thrombosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory distress			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Confusional state			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Cytomegalovirus test positive			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutrophil count decreased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oxygen saturation decreased			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural			

complications			
Fall			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femur fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaw fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple fractures			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple injuries			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Cardiac arrest				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure chronic				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure congestive				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardio-respiratory arrest				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiopulmonary failure				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Coronary artery disease				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Left ventricular dysfunction				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocardial infarction				
subjects affected / exposed	0 / 32 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sinus tachycardia				

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular tachycardia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lethargy			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paraparesis			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Status epilepticus</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Syncope</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Transient ischaemic attack</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Vascular encephalopathy</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Aplastic anaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Autoimmune haemolytic anaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Febrile neutropenia</b>			

subjects affected / exposed	2 / 32 (6.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Haemolytic anaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Haemorrhagic anaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Leukopenia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Neutropenia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Pancytopenia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Thrombocytopenia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Thrombocytopenic purpura</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Eye disorders</b>			
Optic atrophy			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal artery occlusion			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Duodenal perforation			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Faecalith			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nausea</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Small intestinal obstruction</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Stomatitis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Vomiting</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hepatobiliary disorders</b>			
Drug-induced liver injury			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hepatorenal syndrome</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Hyperbilirubinaemia</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Portal vein thrombosis</b>			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Skin and subcutaneous tissue disorders</b>			
<b>Dermatitis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Paraneoplastic pemphigus</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Stevens-Johnson syndrome</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Toxic epidermal necrolysis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Urticaria</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Renal and urinary disorders</b>			
<b>Acute kidney injury</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Nephrolithiasis</b>			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Renal failure</b>			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract inflammation			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pathological fracture			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acinetobacter bacteraemia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical pneumonia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Bronchopulmonary aspergillosis subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Candida infection subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile infection subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cytomegalovirus chorioretinitis subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cytomegalovirus infection subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device related sepsis subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysentery subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia urinary tract infection			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes ophthalmic			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster disseminated			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Klebsiella sepsis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenic infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal candidiasis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peritonitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumocystis jirovecii infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumocystis jirovecii pneumonia			

subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative abscess			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary sepsis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Septic shock			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal skin infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subcutaneous abscess			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tuberculosis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Varicella			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			

subjects affected / exposed	0 / 32 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Total	OFA + BENDA	BENDA
Total subjects affected by non-serious adverse events			
subjects affected / exposed	320 / 342 (93.57%)	158 / 172 (91.86%)	162 / 170 (95.29%)
Vascular disorders			
Hypertension			
subjects affected / exposed	21 / 342 (6.14%)	10 / 172 (5.81%)	6 / 170 (3.53%)
occurrences (all)	0	10	6
Hypotension			
subjects affected / exposed	16 / 342 (4.68%)	9 / 172 (5.23%)	6 / 170 (3.53%)
occurrences (all)	0	9	7
Phlebitis			
subjects affected / exposed	16 / 342 (4.68%)	6 / 172 (3.49%)	10 / 170 (5.88%)
occurrences (all)	0	6	12
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	44 / 342 (12.87%)	17 / 172 (9.88%)	27 / 170 (15.88%)
occurrences (all)	0	26	31
Chills			
subjects affected / exposed	25 / 342 (7.31%)	9 / 172 (5.23%)	15 / 170 (8.82%)
occurrences (all)	0	12	19
Fatigue			
subjects affected / exposed	101 / 342 (29.53%)	41 / 172 (23.84%)	59 / 170 (34.71%)
occurrences (all)	0	53	69
Influenza like illness			
subjects affected / exposed	13 / 342 (3.80%)	9 / 172 (5.23%)	4 / 170 (2.35%)
occurrences (all)	0	9	6
Malaise			
subjects affected / exposed	15 / 342 (4.39%)	3 / 172 (1.74%)	12 / 170 (7.06%)
occurrences (all)	0	3	16
Mucosal inflammation			

subjects affected / exposed occurrences (all)	24 / 342 (7.02%) 0	9 / 172 (5.23%) 10	14 / 170 (8.24%) 16
Oedema peripheral subjects affected / exposed occurrences (all)	23 / 342 (6.73%) 0	9 / 172 (5.23%) 15	14 / 170 (8.24%) 15
Pyrexia subjects affected / exposed occurrences (all)	78 / 342 (22.81%) 0	33 / 172 (19.19%) 54	44 / 170 (25.88%) 62
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	68 / 342 (19.88%) 0	38 / 172 (22.09%) 42	27 / 170 (15.88%) 31
Dyspnoea subjects affected / exposed occurrences (all)	38 / 342 (11.11%) 0	14 / 172 (8.14%) 16	21 / 170 (12.35%) 23
Oropharyngeal pain subjects affected / exposed occurrences (all)	14 / 342 (4.09%) 0	10 / 172 (5.81%) 11	3 / 170 (1.76%) 3
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	26 / 342 (7.60%) 0	15 / 172 (8.72%) 18	8 / 170 (4.71%) 8
Investigations			
Neutrophil count decreased subjects affected / exposed occurrences (all)	26 / 342 (7.60%) 0	13 / 172 (7.56%) 27	13 / 170 (7.65%) 24
Platelet count decreased subjects affected / exposed occurrences (all)	26 / 342 (7.60%) 0	12 / 172 (6.98%) 15	14 / 170 (8.24%) 18
Weight decreased subjects affected / exposed occurrences (all)	31 / 342 (9.06%) 0	11 / 172 (6.40%) 11	20 / 170 (11.76%) 20
White blood cell count decreased subjects affected / exposed occurrences (all)	20 / 342 (5.85%) 0	11 / 172 (6.40%) 17	9 / 170 (5.29%) 15
Injury, poisoning and procedural complications			

Infusion related reaction subjects affected / exposed occurrences (all)	25 / 342 (7.31%) 0	19 / 172 (11.05%) 27	2 / 170 (1.18%) 2
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	22 / 342 (6.43%) 0	14 / 172 (8.14%) 16	7 / 170 (4.12%) 7
Dysgeusia subjects affected / exposed occurrences (all)	29 / 342 (8.48%) 0	9 / 172 (5.23%) 9	20 / 170 (11.76%) 20
Headache subjects affected / exposed occurrences (all)	56 / 342 (16.37%) 0	31 / 172 (18.02%) 40	21 / 170 (12.35%) 27
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	77 / 342 (22.51%) 0	31 / 172 (18.02%) 41	46 / 170 (27.06%) 65
Leukopenia subjects affected / exposed occurrences (all)	46 / 342 (13.45%) 0	25 / 172 (14.53%) 43	21 / 170 (12.35%) 31
Lymphopenia subjects affected / exposed occurrences (all)	34 / 342 (9.94%) 0	17 / 172 (9.88%) 25	17 / 170 (10.00%) 18
Neutropenia subjects affected / exposed occurrences (all)	141 / 342 (41.23%) 0	66 / 172 (38.37%) 132	74 / 170 (43.53%) 145
Thrombocytopenia subjects affected / exposed occurrences (all)	77 / 342 (22.51%) 0	30 / 172 (17.44%) 37	46 / 170 (27.06%) 74
Eye disorders			
Vitreous floaters subjects affected / exposed occurrences (all)	3 / 342 (0.88%) 0	1 / 172 (0.58%) 1	0 / 170 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	20 / 342 (5.85%) 0	9 / 172 (5.23%) 10	11 / 170 (6.47%) 12

Constipation			
subjects affected / exposed	72 / 342 (21.05%)	29 / 172 (16.86%)	40 / 170 (23.53%)
occurrences (all)	0	39	46
Diarrhoea			
subjects affected / exposed	75 / 342 (21.93%)	35 / 172 (20.35%)	40 / 170 (23.53%)
occurrences (all)	0	56	53
Dry mouth			
subjects affected / exposed	16 / 342 (4.68%)	7 / 172 (4.07%)	9 / 170 (5.29%)
occurrences (all)	0	9	10
Dyspepsia			
subjects affected / exposed	16 / 342 (4.68%)	9 / 172 (5.23%)	7 / 170 (4.12%)
occurrences (all)	0	10	7
Nausea			
subjects affected / exposed	155 / 342 (45.32%)	62 / 172 (36.05%)	93 / 170 (54.71%)
occurrences (all)	0	101	151
Stomatitis			
subjects affected / exposed	19 / 342 (5.56%)	6 / 172 (3.49%)	12 / 170 (7.06%)
occurrences (all)	0	7	13
Vomiting			
subjects affected / exposed	66 / 342 (19.30%)	25 / 172 (14.53%)	40 / 170 (23.53%)
occurrences (all)	0	36	58
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	10 / 342 (2.92%)	4 / 172 (2.33%)	4 / 170 (2.35%)
occurrences (all)	0	4	4
Erythema			
subjects affected / exposed	12 / 342 (3.51%)	7 / 172 (4.07%)	4 / 170 (2.35%)
occurrences (all)	0	11	4
Pruritus			
subjects affected / exposed	40 / 342 (11.70%)	24 / 172 (13.95%)	12 / 170 (7.06%)
occurrences (all)	0	32	19
Rash			
subjects affected / exposed	50 / 342 (14.62%)	33 / 172 (19.19%)	15 / 170 (8.82%)
occurrences (all)	0	47	16
Urticaria			

subjects affected / exposed occurrences (all)	18 / 342 (5.26%) 0	13 / 172 (7.56%) 14	1 / 170 (0.59%) 1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	25 / 342 (7.31%)	13 / 172 (7.56%)	12 / 170 (7.06%)
occurrences (all)	0	14	13
Back pain			
subjects affected / exposed	20 / 342 (5.85%)	13 / 172 (7.56%)	5 / 170 (2.94%)
occurrences (all)	0	13	5
Musculoskeletal pain			
subjects affected / exposed	7 / 342 (2.05%)	0 / 172 (0.00%)	5 / 170 (2.94%)
occurrences (all)	0	0	5
Myalgia			
subjects affected / exposed	15 / 342 (4.39%)	4 / 172 (2.33%)	9 / 170 (5.29%)
occurrences (all)	0	4	10
Pain in extremity			
subjects affected / exposed	19 / 342 (5.56%)	11 / 172 (6.40%)	8 / 170 (4.71%)
occurrences (all)	0	14	10
Infections and infestations			
Bronchitis			
subjects affected / exposed	30 / 342 (8.77%)	19 / 172 (11.05%)	11 / 170 (6.47%)
occurrences (all)	0	23	13
Herpes zoster			
subjects affected / exposed	20 / 342 (5.85%)	9 / 172 (5.23%)	10 / 170 (5.88%)
occurrences (all)	0	9	11
Nasopharyngitis			
subjects affected / exposed	42 / 342 (12.28%)	27 / 172 (15.70%)	14 / 170 (8.24%)
occurrences (all)	0	36	17
Oral herpes			
subjects affected / exposed	19 / 342 (5.56%)	9 / 172 (5.23%)	10 / 170 (5.88%)
occurrences (all)	0	9	10
Sinusitis			
subjects affected / exposed	17 / 342 (4.97%)	10 / 172 (5.81%)	7 / 170 (4.12%)
occurrences (all)	0	11	7
Upper respiratory tract infection			

subjects affected / exposed	29 / 342 (8.48%)	12 / 172 (6.98%)	15 / 170 (8.82%)
occurrences (all)	0	17	16
Urinary tract infection			
subjects affected / exposed	21 / 342 (6.14%)	11 / 172 (6.40%)	7 / 170 (4.12%)
occurrences (all)	0	11	9
<b>Metabolism and nutrition disorders</b>			
Decreased appetite			
subjects affected / exposed	69 / 342 (20.18%)	24 / 172 (13.95%)	44 / 170 (25.88%)
occurrences (all)	0	28	53
Diabetes mellitus			
subjects affected / exposed	3 / 342 (0.88%)	1 / 172 (0.58%)	0 / 170 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	17 / 342 (4.97%)	9 / 172 (5.23%)	8 / 170 (4.71%)
occurrences (all)	0	11	9
Hyperkalaemia			
subjects affected / exposed	3 / 342 (0.88%)	0 / 172 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	27 / 342 (7.89%)	11 / 172 (6.40%)	15 / 170 (8.82%)
occurrences (all)	0	14	20

<b>Non-serious adverse events</b>	Optional OFA		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 32 (65.63%)		
<b>Vascular disorders</b>			
Hypertension			
subjects affected / exposed	5 / 32 (15.63%)		
occurrences (all)	6		
Hypotension			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Phlebitis			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
<b>General disorders and administration site conditions</b>			

Asthenia			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	5 / 32 (15.63%)		
occurrences (all)	5		
Influenza like illness			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	0 / 32 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	2		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	6 / 32 (18.75%)		
occurrences (all)	8		
Dyspnoea			
subjects affected / exposed	4 / 32 (12.50%)		
occurrences (all)	5		
Oropharyngeal pain			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		
Psychiatric disorders			

Insomnia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3		
Investigations			
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Weight decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4		
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
Dysgeusia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Headache subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 5		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Leukopenia			

subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
Lymphopenia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Neutropenia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 4		
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
Eye disorders Vitreous floaters subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
Constipation subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4		
Diarrhoea subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3		
Dry mouth subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Dyspepsia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
Nausea subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 6		
Stomatitis			

<p>subjects affected / exposed occurrences (all)</p> <p>Vomiting subjects affected / exposed occurrences (all)</p>	<p>1 / 32 (3.13%) 1</p> <p>2 / 32 (6.25%) 3</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>Dry skin subjects affected / exposed occurrences (all)</p> <p>Erythema subjects affected / exposed occurrences (all)</p> <p>Pruritus subjects affected / exposed occurrences (all)</p> <p>Rash subjects affected / exposed occurrences (all)</p> <p>Urticaria subjects affected / exposed occurrences (all)</p>	<p>2 / 32 (6.25%) 2</p> <p>2 / 32 (6.25%) 2</p> <p>4 / 32 (12.50%) 4</p> <p>2 / 32 (6.25%) 2</p> <p>4 / 32 (12.50%) 4</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia subjects affected / exposed occurrences (all)</p> <p>Back pain subjects affected / exposed occurrences (all)</p> <p>Musculoskeletal pain subjects affected / exposed occurrences (all)</p> <p>Myalgia subjects affected / exposed occurrences (all)</p> <p>Pain in extremity</p>	<p>0 / 32 (0.00%) 0</p> <p>2 / 32 (6.25%) 2</p> <p>2 / 32 (6.25%) 2</p> <p>2 / 32 (6.25%) 2</p>		

subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
<b>Herpes zoster</b>			
subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
<b>Nasopharyngitis</b>			
subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
<b>Oral herpes</b>			
subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1		
<b>Sinusitis</b>			
subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
<b>Upper respiratory tract infection</b>			
subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 5		
<b>Urinary tract infection</b>			
subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 4		
<b>Metabolism and nutrition disorders</b>			
<b>Decreased appetite</b>			
subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3		
<b>Diabetes mellitus</b>			
subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
<b>Hyperglycaemia</b>			
subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0		
<b>Hyperkalaemia</b>			

subjects affected / exposed	2 / 32 (6.25%)		
occurrences (all)	3		
Hypokalaemia			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 November 2009	<p>Logo updated to describe meaning of COMPLEMENT.</p> <p>Sponsor information page: Medical Monitor contact information updated. Addition of secondary endpoint: Overall response rate to optional ofatumumab monotherapy in subjects in Arm B who progress during or following single-agent bendamustine.</p> <p>Spelling correction in the Exclusion Criteria: fludaranine replaced by fludarabine and addition of criteria excluding prior treatment with anti-CD20 mAb within 3 months of randomization.</p> <p>Administered bendamustine therapy as monotherapy or in combination with ofatumumab for up to 8 cycles.</p> <p>There were a total of 12 ofatumumab infusions in Arm A. Ofatumumab was given on day 1 of each cycle of bendamustine as long as subjects in Arm A received bendamustine. Once subjects in Arm A completed bendamustine therapy, the remaining doses of ofatumumab were be given monthly until all 12 doses were completed.</p>
12 May 2010	<p>Introduction includes additional rationale for infusion of 1000 mg dose upon first infusion in and 2000 mg dose upon 2nd infusion (for those who receive ofatumumab following PD in Arm B) at protocol defined rate.</p> <p>Inclusion criterion #1 updated: Removed reference to bulky stage.</p> <p>Clarified screening procedures.</p> <p>Inclusion criterion #2 updated: to allow CT imaging performed at least 60 days after the last dose of rituximab-based therapy. Modified text for prior rituximab infusions.</p> <p>Exclusion criterion #3 updated timeframe from previous autologous stem cell transplant, or fludarabine therapy, or radioimmunotherapy from past 12 months to last 6 months.</p> <p>Exclusion criterion #5 updated timeframe for high dose steroids (7 consecutive days) and dose of prednisone before randomization (100 mg).</p> <p>Exclusion criterion #7 update to exclude prior use of any monoclonal antibody (other than anti-CD20) within 3 months of randomization and anti-CD20 therapy first dose was administered 60 days prior to randomization.</p> <p>Exclusion criteria #15 updated: specifies liver metastases related to indolent NHL.</p> <p>Exclusion criterion #18 updated to include hypersensitivity to bendamustine and mannitol.</p> <p>Removed exclusion criterion #20 since it duplicated criterion #7. Subjects in Arm B who chose to receive optional ofatumumab monotherapy received ofatumumab 1000 mg for the first dose. CT scans, lymphoma symptoms, and response assessments will be done Days 84, 168, and 252 (<math>\pm 7</math> days).</p> <p>Whole body CT scan (contrast imaging of neck when lesion is palpable, thorax, abdomen, pelvis). Rmved mention of physical examination as part of CR assessment.</p> <p>Updated FACT-Lym Version 4, removed FACT-G Patient Reported Outcomes (PRO) questionnaire. HACA test done before first dose of ofatumumab.</p>

19 January 2012	<p>CT scans may be whole body or done according to local practice. No required bone marrow aspirate Known and exploratory prognostic markers and exploratory pharmacogenetic research objectives clarified.</p> <p>Inclusion Criterion #1: Type of previous biopsy changed from "lymph node" to "tissue" biopsy. Inclusion Criterion #1 clarified. Tumor verified to be CD20+ positive from a previous or current tissue biopsy.</p> <p>No longer excluded fludarabine and radioimmunotherapy.</p> <p>No longer excluded external beam radiation therapy to pelvis and to bony disease to the cranium, mediastinum, and axilla, or &gt; 3 vertebral bodies.</p> <p>Removed Exclusion criterion restricting anti-CD20 antibody within the last 60 days. Copy of documentation confirming PD (for example, an imaging report, clinical documentation) after subject deemed unresponsive or relapsed to rituximab-based regimen was required.</p> <p>Follow-up visits begin 2 months after PD is confirmed by CT scan. For all other responses, follow-up visits begin on Day 336 (this is 3 months after Day 252) for both arms.</p> <p>Withdrawal Criteria: If a subject withdrew from study drug but did not withdraw from the study, the subject was expected to complete all scheduled visits without study drug. The subject may then enter follow-up.</p>
07 February 2013	<p>Edited text due to updates found in Investigator Brochure update. Correction in footnotes to Time and Events Table (Appendix 1): baseline CT scans required <math>\leq 1</math> month of randomization. Correct reference for Table updated.</p> <p>High dose steroids <math>\geq 25</math> mg prednisolone/day (or equivalent) for 7 consecutive days were excluded. Updated from excluding <math>\geq 100</math> mg prednisolone/day (or equivalent). All SAEs regardless of causality were reported from 61 days after the last dose of investigational product to the end of the follow-up period or until initiation of subsequent antilymphoma therapy is initiated. Any SAE brought to the investigator's attention after the start of subsequent anti-lymphoma therapy and considered by the investigator as possibly related to either ofatumumab or bendamustine were to be reported to GSK.</p> <p>Additional biochemistry testing added to time and events table for ofatumumab monotherapy following progression in Arm B.</p> <p>For Japan only: additional directions for Hepatitis monitoring added to an Appendix. Investigator Brochure reference updated.</p>
07 February 2013	<p>At the request of the French regulatory agency, safety related information from the Study Procedures Manual (SPM) was added.</p>
02 December 2013	<p>Added additional instructions for monitoring subjects who were HBsAg negative, anti-HBc positive and HBV DNA negative. This instruction was added to the relevant Time and Events tables.</p> <p>Exclusion criteria now specified that physician experienced in care and management of subjects with Hepatitis B manage/treat subjects who were anti-HBc positive must be consulted. Changes for countries using Amendment 4 included specific details on how to manage AEs and SAEs such as infusion reactions, tumor lysis syndrome, progressive multifocal leukoencephalopathy and hepatitis were described.</p>
07 July 2015	<p>Authors and Sponsor Contact Information Updated</p> <p>Table of Contents updated to include Appendix 15: Protocol Changes for Amendment #7 from Amendment #6.</p> <p>Total number of events increased to 259 events.</p> <p>Total study duration increased to 77 months.</p> <p>Total accrual rate decreased to 5.1pt/month.</p> <p>Clarification of randomization strategy.</p> <p>An Interim Analysis added for efficacy when two thirds of IRR events occurred.</p> <p>Details of a further Independent Data Monitoring Committee (IDMC) added to review the safety, efficacy, and futility data and recommended whether the study should continue without any changes, be stopped to further enrollment, or be terminated.</p> <p>Liver stopping criteria updated to reflect stopping criteria applies to all patients on study, regardless of Arm assignment.</p> <p>Clarification of instructions regarding how patients moved into Survival Follow-Up.</p> <p>Amendment Republished due to typographical error.</p>

18 March 2016	The purpose of this protocol amendment was to: - Delete or replace references to GSK or its staff with that of Novartis and its authorized agents to align with the change of sponsorship - Make administrative changes to align with Novartis processes and procedures
13 April 2017	The purpose of amendment 9 was to revise the total number of events required for the primary analysis of the primary end point PFS. The primary analysis was planned after reaching 259 PFS events as determined by an Independent Review Committee (IRC). Based on the current status of the study and PFS event count by IRC, it was highly unlikely that the 259 PFS events would be achieved.

Notes:

---

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <a href="https://www.novctrd.com/CtrdWeb/home.nov">https://www.novctrd.com/CtrdWeb/home.nov</a> for complete trial results.
---

Notes: